Electrochemiluminescence (ECL) is a chemiluminescence phenomenon triggered by electrochemical reactions at the electrode surface, which has gradually become a high-sensitivity detection technology due to its low background, simple instrumentation, and high sensitivity. Therein, potential-resolved ECL refers to the generation of two or more ECL signals with distinct potentials and wavelengths during an electrochemical process. This unique capability enables simultaneous multi-signal outputs, making potential-resolved ECL particularly promising for self-calibration and multiplexed detection strategies. In this review, we focus on two critical aspects: on the one hand, the advancement of traditional ECL luminophores and potential-resolved ECL systems was reviewed, which were classified, respectively, into three categories to be introduced in detail (inorganic, organic and nanomaterial-based ECL luminophores or potential-resolved ECL of metal–organic complexes, layer-by-layer-modified electrodes, and nanomaterials). On the other hand, we summarized ECL detection strategies based on potential-resolved ECL systems and the application of these protocols in disease biomarker detection, which results in two categories (self-calibration strategies and multi-target strategies) for discussion. In this work, we aim to inspire investigators to explore novel ECL luminophores and design detection strategies with high performance, which could provide strong support for precision medicine, personalized assessment, portable medical devices, and the digital transformation of healthcare.
Alterations in serum metabolite composition have been increasingly associated with systemic lupus erythematosus (SLE), yet the direct effects of these metabolites on immune cell function remain poorly defined. This study aimed to identify peripheral blood metabolites associated with SLE and evaluate their impact on apoptosis and cytokine secretion in lymphocytes derived from SLE patients. We performed a two-sample Mendelian randomization (MR) analysis to investigate the relationship between 565 serum metabolites and SLE, using the inverse-variance weighted model as the primary analytical approach. Significant findings were cross-validated using previously published untargeted metabolomics data based on liquid chromatography-mass spectrometry (LC-MS). In functional experiments, lymphocytes isolated from SLE patients were stimulated with target metabolites, followed by assessment of apoptosis and cytokine secretion. MR analysis identified 28 metabolites significantly associated with SLE. Of these, cholesterol (OR = 1.462, 95% CI: 1.100-1.940, P = 0.008) and stearamide (OR = 0.125, 95% CI: 0.020-0.660, P = 0.014) were validated through LC-MS and found to be elevated in SLE patients. Receiver operating characteristic analysis demonstrated strong diagnostic performance (AUC = 0.999 for cholesterol; AUC = 1.000 for stearamide). Functionally, both metabolites induced increased apoptosis and elevated secretion of TNF-α, IFN-γ, and TGF-β1 in SLE lymphocytes. In summary, our integrated approach combining genetic association, metabolite profiling, and functional assays reveals that cholesterol may contribute to immune dysregulation in SLE. Although stearamide showed a negative association with SLE risk in MR analysis, its in vitro effects mirrored those of cholesterol, suggesting a complex and context-dependent role. These findings underscore the importance of lipid metabolism in SLE and support further mechanistic and clinical investigation of its immunological impact.
Small cell lung cancer (SCLC) is the most aggressive subtype with high mortality rates due to the lack of specific diagnostic biomarkers to delay the optimal opportunity for treatment. Traditional biomarkers, such as neuron-specific enolase (NSE) or pro-gastrin-releasing peptide (ProGRP), have insufficient specificity and sensitivity to meet the demands of clinical diagnosis. Exosome and its contents have become burgeoning cancer biomarkers due to their diverse molecular cargo to achieve intercellular communication. Herein, a novel machine learning strategy was reported for rapid, efficient screening of biomarkers and identified an optimal exosome RNA combination as diagnostic biomarker of SCLC. Firstly, RNA sequencing data from 111 SCLC patients and 362 healthy controls were obtained from the exoRBase 2.0 and 3.0 databases. The machine learning methods were employed to select specific RNA by using 20 iterations with 10-fold nested cross-validation for SCLC diagnosis. Then, an optimal combination of three exosome RNAs (LINC00989, CXCL5, and MAP3K7CL) was confirmed and achieved excellent diagnostic performance (area under the curve (AUC) of 0.950, sensitivity of 0.936, and specificity of 0.892). Finally, an independent validation cohort containing tissue-based RNA expression data for two biomarkers (CXCL5 and MAP3K7CL) from 79 SCLC patients and 7 standard controls was used to evaluate the diagnostic performance of the selected RNAs. The results demonstrated modest diagnostic performance in tissue samples (AUC = 0.718) with two biomarkers, indicating potential cross-tissue applicability despite the limitations of incomplete biomarker coverage. In addition, a specificity analysis of exosome RNA data, including gastric cancer, hepatocellular carcinoma, and breast cancer, demonstrated significant specificity for SCLC. Therefore, the novel biomarker screening strategy integrating nested cross-validation with multiple machine learning algorithms successfully established to offer a potentially valuable protocol for early SCLC diagnosis and other cancers.
17 October 2025 in Journal of Visualized Experiments
Alterations in serum metabolite composition have been increasingly associated with systemic lupus erythematosus (SLE), yet the direct effects of these metabolites on immune cell function remain poorly defined. This study aimed to identify peripheral blood metabolites associated with SLE and evaluate their impact on apoptosis and cytokine secretion in lymphocytes derived from SLE patients. We performed a two-sample Mendelian randomization (MR) analysis to investigate the relationship between 565 serum metabolites and SLE, using the inverse-variance weighted model as the primary analytical approach. Significant findings were cross-validated using previously published untargeted metabolomics data based on liquid chromatography-mass spectrometry (LC-MS). In functional experiments, lymphocytes isolated from SLE patients were stimulated with target metabolites, followed by assessment of apoptosis and cytokine secretion. MR analysis identified 28 metabolites significantly associated with SLE. Of these, cholesterol (OR = 1.462, 95% CI: 1.100-1.940, P = 0.008) and stearamide (OR = 0.125, 95% CI: 0.020-0.660, P = 0.014) were validated through LC-MS and found to be elevated in SLE patients. Receiver operating characteristic analysis demonstrated strong diagnostic performance (AUC = 0.999 for cholesterol; AUC = 1.000 for stearamide). Functionally, both metabolites induced increased apoptosis and elevated secretion of TNF-α, IFN-γ, and TGF-β1 in SLE lymphocytes. In summary, our integrated approach combining genetic association, metabolite profiling, and functional assays reveals that cholesterol may contribute to immune dysregulation in SLE. Although stearamide showed a negative association with SLE risk in MR analysis, its in vitro effects mirrored those of cholesterol, suggesting a complex and context-dependent role. These findings underscore the importance of lipid metabolism in SLE and support further mechanistic and clinical investigation of its immunological impact.